Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa.

Trial Profile

Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Amikacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Insmed
  • Most Recent Events

    • 11 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 22 Aug 2012 Status changed from suspended to not yet recruiting as reported by ClinicalTrials.gov.
    • 08 May 2012 The US FDA lifts the clinical hold on inhaled amikacin, but the status of this trial is being evaluated by Insmed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top